Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BDTX Black Diamond Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: BDTX
Price (delayed)
$2.58
Market cap
$146.71M
P/E Ratio
32.25
Dividend/share
N/A
EPS
$0.08
Enterprise value
$65.34M
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond
Highlights
The net income has soared by 107% from the previous quarter and by 106% YoY
Black Diamond Therapeutics's EPS has surged by 106% QoQ and by 105% YoY
Sector: Healthcare
Industry: Biotechnology
Key stats
What are the main financial stats of BDTX
Market
Valuations
Earnings
Shares outstanding
56.86M
Market cap
$146.71M
Enterprise value
$65.34M
Price to earnings (P/E)
32.25
Price to book (P/B)
1.03
Price to sales (P/S)
2.09
EV/EBIT
12.83
EV/EBITDA
12.02
EV/Sales
0.93
Revenue
$70M
Gross profit
$70M
Operating income
-$4.01M
Net income
$5.09M
EBIT
$5.09M
EBITDA
$5.44M
Free cash flow
$12.41M
Per share
Balance sheet
Liquidity
EPS
$0.08
EPS diluted
$0.06
Free cash flow per share
$0.22
Book value per share
$2.5
Revenue per share
$1.24
TBVPS
$3.11
Total assets
$176.25M
Total liabilities
$34.73M
Debt
$17.88M
Equity
$141.52M
Working capital
$138.83M
Debt to equity
0.13
Current ratio
9.24
Quick ratio
9.09
Net debt/EBITDA
-14.97
Margins
Efficiency
Dividend
EBITDA margin
7.8%
Gross margin
100%
Net margin
7.3%
Operating margin
-5.7%
Return on assets
3.5%
Return on equity
4.7%
Return on invested capital
5.2%
Return on capital employed
3.2%
Return on sales
7.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BDTX stock price
How has the Black Diamond Therapeutics stock price performed over time
Intraday
-0.77%
1 week
4.88%
1 month
3.2%
1 year
-41.89%
YTD
20.56%
QTD
4.03%
Financial performance
How have Black Diamond Therapeutics's revenue and profit performed over time
Revenue
$70M
Gross profit
$70M
Operating income
-$4.01M
Net income
$5.09M
Gross margin
100%
Net margin
7.3%
The net income has soared by 107% from the previous quarter and by 106% YoY
BDTX's operating income has soared by 95% YoY and by 95% QoQ
Price vs fundamentals
How does BDTX's price correlate with its fundamentals
Growth
What is Black Diamond Therapeutics's growth rate over time
Valuation
What is Black Diamond Therapeutics stock price valuation
P/E
32.25
P/B
1.03
P/S
2.09
EV/EBIT
12.83
EV/EBITDA
12.02
EV/Sales
0.93
Black Diamond Therapeutics's EPS has surged by 106% QoQ and by 105% YoY
The company's equity has surged by 70% QoQ and by 36% YoY
The P/B is 39% lower than the last 4 quarters average of 1.7 and 36% lower than the 5-year quarterly average of 1.6
Efficiency
How efficient is Black Diamond Therapeutics business performance
BDTX's return on invested capital has surged by 108% since the previous quarter and by 107% year-on-year
The ROA has soared by 107% QoQ and by 107% YoY
Black Diamond Therapeutics's ROE has soared by 107% from the previous quarter and by 106% YoY
Dividends
What is BDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BDTX.
Financial health
How did Black Diamond Therapeutics financials performed over time
BDTX's current ratio has surged by 88% since the previous quarter and by 31% year-on-year
The quick ratio has soared by 88% from the previous quarter and by 32% YoY
The debt is 87% smaller than the equity
The company's equity has surged by 70% QoQ and by 36% YoY
Black Diamond Therapeutics's debt to equity has decreased by 43% QoQ and by 35% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.